These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 21999763)

  • 1. Best practices to reduce the risk of drug-drug interactions: opportunities for managed care.
    Fanciullo GJ; Washington T
    Am J Manag Care; 2011 Sep; 17 Suppl 11():S299-304. PubMed ID: 21999763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantifying the impact of drug-drug interactions associated with opioids.
    Pergolizzi JV
    Am J Manag Care; 2011 Sep; 17 Suppl 11():S288-92. PubMed ID: 21999761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of drug-drug interactions: considerations for special populations--focus on opioid use in the elderly and long term care.
    Lynch T
    Am J Manag Care; 2011 Sep; 17 Suppl 11():S293-8. PubMed ID: 21999762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opioid pharmacokinetic drug-drug interactions.
    Overholser BR; Foster DR
    Am J Manag Care; 2011 Sep; 17 Suppl 11():S276-87. PubMed ID: 21999760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic pain: reducing costs through early implementation of adherence testing and recognition of opioid misuse.
    McCarberg BH
    Postgrad Med; 2011 Nov; 123(6):132-9. PubMed ID: 22104462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Managing co-occurring substance use and pain disorders.
    Miotto K; Kaufman A; Kong A; Jun G; Schwartz J
    Psychiatr Clin North Am; 2012 Jun; 35(2):393-409. PubMed ID: 22640762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exposure to potential CYP450 pharmacokinetic drug-drug interactions among osteoarthritis patients: incremental risk of multiple prescriptions.
    Pergolizzi JV; Labhsetwar SA; Puenpatom RA; Joo S; Ben-Joseph R; Summers KH
    Pain Pract; 2011; 11(4):325-36. PubMed ID: 21199317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polypharmacy management in Medicare managed care: changes in prescribing by primary care physicians resulting from a program promoting medication reviews.
    Fillit HM; Futterman R; Orland BI; Chim T; Susnow L; Picariello GP; Scheye EC; Spoeri RK; Roglieri JL; Warburton SW
    Am J Manag Care; 1999 May; 5(5):587-94. PubMed ID: 10537865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk assessment and counseling behaviors of healthcare professionals managing patients with chronic pain: a national multifaceted assessment of physicians, pharmacists, and their patients.
    Salinas GD; Susalka D; Burton BS; Roepke N; Evanyo K; Biondi D; Nicholson S
    J Opioid Manag; 2012; 8(5):273-84. PubMed ID: 23247904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polypharmacy in the elderly: maximizing benefit, minimizing harm.
    Ballentine NH
    Crit Care Nurs Q; 2008; 31(1):40-5. PubMed ID: 18316935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psychotropic medications and falls in older adults.
    Van Leuven K
    J Psychosoc Nurs Ment Health Serv; 2010 Sep; 48(9):35-43. PubMed ID: 20795592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence and risk of potential cytochrome P450-mediated drug-drug interactions in older hospitalized patients with polypharmacy.
    Doan J; Zakrzewski-Jakubiak H; Roy J; Turgeon J; Tannenbaum C
    Ann Pharmacother; 2013 Mar; 47(3):324-32. PubMed ID: 23482734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic implications of potential drug-drug interactions in chronic pain patients.
    Taylor R; V Pergolizzi J; Puenpatom RA; Summers KH
    Expert Rev Pharmacoecon Outcomes Res; 2013 Dec; 13(6):725-34. PubMed ID: 24219048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polypharmacy in patients with advanced cancer and pain: a European cross-sectional study of 2282 patients.
    Kotlinska-Lemieszek A; Paulsen O; Kaasa S; Klepstad P
    J Pain Symptom Manage; 2014 Dec; 48(6):1145-59. PubMed ID: 24780183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A critical assessment of opioid treatment adherence using urine drug testing in chronic pain management.
    McCarberg BH
    Postgrad Med; 2011 Nov; 123(6):124-31. PubMed ID: 22104461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Managing the pain of traumatic injury.
    Alpen MA; Morse C
    Crit Care Nurs Clin North Am; 2001 Jun; 13(2):243-57. PubMed ID: 11866406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of exposure to potential CYP450 pharmacokinetic drug-drug interactions among patients with chronic low back pain taking opioids.
    Pergolizzi JV; Labhsetwar SA; Puenpatom RA; Joo S; Ben-Joseph RH; Summers KH
    Pain Pract; 2011; 11(3):230-9. PubMed ID: 20807350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The opioid renewal clinic: a primary care, managed approach to opioid therapy in chronic pain patients at risk for substance abuse.
    Wiedemer NL; Harden PS; Arndt IO; Gallagher RM
    Pain Med; 2007; 8(7):573-84. PubMed ID: 17883742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prevalence of opioid-related major potential drug-drug interactions and their impact on health care costs in chronic pain patients.
    Pergolizzi JV; Ma L; Foster DR; Overholser BR; Sowinski KM; Taylor R; Summers KH
    J Manag Care Spec Pharm; 2014 May; 20(5):467-76. PubMed ID: 24761818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.